12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LY2228820: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 54 patients with advanced cancer showed that LY2228820 produced 15 cases of stable disease. The maximum tolerated dose (MTD) was twice-daily 420 mg LY2228820, however twice-daily 300 mg LY2228820 was selected as the recommended...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >